![]() ![]() in Engineering Sciences from the University of California, San Diego and her M.B.A. Previously, she was also General Partner at dRx Capital, a $100mn venture fund founded in 2015 by Novartis and Qualcomm Ventures focused on early stage digital health investing.Ĭarolyne earned her B.S. At Novartis, she led the Global Cardio-Metabolic Franchise’s Business Development and Licensing efforts, where she was responsible for driving the external strategy and securing strategic assets to expand the portfolio. Earlier in her career, she held leadership roles in the Global Business Development & Licensing group at Novartis Pharmaceuticals for over 13 years, where she gained extensive experience in structuring and negotiating strategic transactions with both pharmaceutical and biotechnology entities, including collaborations, licensing deals, acquisitions, and equity investments. In this role, she led the transaction team on all deal-related matters, including sourcing and executing transactions as well as supporting J&J’s Lung Cancer Initiative’s early innovation deal making efforts. ![]() Zimmermann joins 4DMT from Johnson & Johnson Innovation where she served as Vice President, Transactions. Carolyne will play a major role in realizing our vision of converting the power of our directed evolution platform into potentially transformative products for patients.” “Her appointment reflects our commitment to unlocking the full potential of our Therapeutic Vector Evolution gene therapy platform, and further empowers the company to achieve its goal of becoming a fully integrated biopharmaceutical leader in gene therapy. “Carolyne’s extensive experience in biotechnology corporate and business development, external innovation, pre-commercial planning, product pipeline strategy and venture investing brings valuable skillsets to 4DMT,” said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. Zimmermann brings nearly 20 years of leadership experience in life sciences corporate and business development from her prior roles at Johnson & Johnson Innovation and Novartis Pharmaceuticals. counsel Chad Jennings on data privacy matters by Bay Area partner Heather Deixler on tax matters by Bay Area partner Grace Lee and on benefits and compensation matters by Bay Area partner Maj Vaseghi.EMERYVILLE, Calif., J(GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced the appointment of Carolyne Zimmermann as Chief Business Officer. partner Elizabeth Richards, Bay Area partner Betty Pang, and Washington, D.C. Advice was also provided on regulatory matters by Washington, D.C. ![]() Latham & Watkins LLP advised 4D Molecular Therapeutics in the offering, with a corporate deal team led by Bay Area partners Mark Roeder and Phillip Stoup, with associates Zuzanna Gruca, Raul Gonzalez, and Chelsi DeTurk. The offering is expected to close on May 9, 2023, subject to satisfaction of customary closing conditions. All of the shares in the offering are to be sold by 4D Molecular Therapeutics. The gross proceeds from the offering are expected to be US$120.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. In addition, 4D Molecular Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting discounts and commissions. ![]() (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, has announced that it priced an upsized underwritten public offering of 7,500,000 shares of its common stock at a public offering price of US$16.00 per share. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |